Tenderwize
Wróć do wyszukiwania

Open-House Discount Agreement for Abaloparatid

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 28, 2028 · 552 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-01 - Abaloparatid

30/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

30 / 100

Złożoność

25 / 100

Czynniki ryzyka

No estimated contract value provided. The financial opportunity cannot be assessed.

Submission must be via email with qualified electronic signature or postal mail with scan. Not using standard e-procure...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Supply of pharmaceutical products containing Abaloparatid to German statutory health insurance funds.
  • Conclusion of discount agreements under § 130c SGB V with uniform conditions.
Pokaż pełne podsumowanie

Open-house procedure for discount agreements (Rabattverträge) for the active substance Abaloparatid under § 130c SGB V. The contracting authority is Techniker Krankenkasse (TK) together with HEK and hkk. This is not a standard public procurement but an open-house model where any eligible pharmaceutical entrepreneur can join during the contract term. The contract runs from 01.03.2026 to 29.02.2028 (max 24 months). No estimated value is provided. Participation is limited to pharmaceutical entrepreneurs with a valid marketing authorization for Abaloparatid. Submission is via email or post, not through the e-procurement portal.

Ryzyka

No estimated contract value provided. The financial opportunity cannot be assessed.

Submission must be via email with qualified electronic signature or postal mail with scan. Not using standard e-procure...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG.
  • Must have a valid marketing authorization for the medicinal product containing Abaloparatid.
  • Must be established in Germany, EU, or EEA.

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria – open-house model, all eligible participants are accepted.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House Discount Agreement for Abaloparatid

Conclusion of discount agreements for the active substance Abaloparatid under § 130c SGB V. Open-house procedure with no exclusivity. Any pharmaceutical entrepreneur meeting eligibility criteria may join at any time during the contract term.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Feb 2026 - Feb 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria – open-house model, all eligible participants are accepted.

Termin

Deadline Feb 28, 2028

Szczegóły zamówienia

Data publikacji
27 Jan 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
62082-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3